BioMarin Pharmaceutical Inc. announced its financial and operating results for the third quarter of 2026, marking a major milestone as quarterly revenue surpassed $1 billion for the first time.
Q3 2026 Financial Highlights and Revenue Growth
For the quarter ended September 30, 2026, San Rafael, California-based BioMarin reported total revenues of $1.025 billion, representing a 32% increase compared to the same period in the previous year. Company leadership attributed the robust performance to a more diversified portfolio following the earlier acquisition of Amicus Therapeutics, alongside heightened global patient demand for its commercial therapies. Metabolic conditions grew by 44% year-over-year, while skeletal conditions saw a 12% increase.
Pipeline Expansion and Future Outlook
Alongside its financial update, BioMarin highlighted ongoing clinical and regulatory progress. The company recently added an investigational Fabry disease asset to its clinical portfolio, which could become the first subcutaneous enzyme therapy for the condition. Additionally, the U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) action date of May 30, 2027, for VOXZOGO® for treating hypochondroplasia (HCH).
Reflecting order timing uncertainties and the impact of two recently announced acquired in-process research and development (IPR&D) charges, BioMarin updated its full-year 2026 financial guidance. Management hosted a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to discuss the quarterly results and ongoing strategy with investors.
